Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients

Jing Quan Zheng, Yi Chou Hou, Cai Mei Zheng, Chien Lin Lu, Wen Chih Liu, Chia Chao Wu, Ming Te Huang, Yuh Feng Lin, Kuo Cheng Lu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia. This study evaluates the possible beneficial effects of combined vitamin D treatment (paricalcitol and cholecalciferol). Methods: Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled. All patients administered 2 mcg/day of paricalcitol and were randomly allocated into control group (placebo) or study group (cholecalciferol) for 16 weeks. Serum 25(OH)D3, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up. Results: iPTH levels decreased in the study group appropriately and were more significantly decreased at 16 weeks. Study group had significantly increased 25(OH)D3 levels. In addition, the study group had significantly increased serum hCAP-18 levels compared with control group. Correlation analysis showed a significant correlation between the percentage increase in serum hCAP-18 and 25(OH)D3 levels. Conclusions: Cholecalciferol, in combination with paricalcitol, additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation. A dose of 5000 IU/week of cholecalciferol could maintain serum 25(OH)D3 levels above 30 ng/dL as early as 8 weeks after beginning supplementation. Doubling of serum cathelicidin levels were noted after 16 weeks of cholecalciferol supplementation in 40% of study patients.

Original languageEnglish
Article number708
JournalNutrients
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

hemodialysis
parathyroid hormone
cholecalciferol
Cholecalciferol
vitamin D
Parathyroid Hormone
Vitamin D
Renal Dialysis
Serum
hyperparathyroidism
hypercalcemia
Hyperphosphatemia
Control Groups
Secondary Hyperparathyroidism
Hypercalcemia
placebos
CAP18 lipopolysaccharide-binding protein
paricalcitol
incidence
Placebos

Keywords

  • Cholecalciferol
  • Human cathelicidin (hCAP-18)
  • Maintenance hemodialysis (HD)
  • Paricalcitol
  • Secondary hyperparathyroidism (SHPT)
  • Study

ASJC Scopus subject areas

  • Food Science

Cite this

Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients. / Zheng, Jing Quan; Hou, Yi Chou; Zheng, Cai Mei; Lu, Chien Lin; Liu, Wen Chih; Wu, Chia Chao; Huang, Ming Te; Lin, Yuh Feng; Lu, Kuo Cheng.

In: Nutrients, Vol. 8, No. 11, 708, 01.11.2016.

Research output: Contribution to journalArticle

@article{242dd65d86e54b42a0a079e97a7b301d,
title = "Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients",
abstract = "Background: Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia. This study evaluates the possible beneficial effects of combined vitamin D treatment (paricalcitol and cholecalciferol). Methods: Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled. All patients administered 2 mcg/day of paricalcitol and were randomly allocated into control group (placebo) or study group (cholecalciferol) for 16 weeks. Serum 25(OH)D3, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up. Results: iPTH levels decreased in the study group appropriately and were more significantly decreased at 16 weeks. Study group had significantly increased 25(OH)D3 levels. In addition, the study group had significantly increased serum hCAP-18 levels compared with control group. Correlation analysis showed a significant correlation between the percentage increase in serum hCAP-18 and 25(OH)D3 levels. Conclusions: Cholecalciferol, in combination with paricalcitol, additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation. A dose of 5000 IU/week of cholecalciferol could maintain serum 25(OH)D3 levels above 30 ng/dL as early as 8 weeks after beginning supplementation. Doubling of serum cathelicidin levels were noted after 16 weeks of cholecalciferol supplementation in 40{\%} of study patients.",
keywords = "Cholecalciferol, Human cathelicidin (hCAP-18), Maintenance hemodialysis (HD), Paricalcitol, Secondary hyperparathyroidism (SHPT), Study",
author = "Zheng, {Jing Quan} and Hou, {Yi Chou} and Zheng, {Cai Mei} and Lu, {Chien Lin} and Liu, {Wen Chih} and Wu, {Chia Chao} and Huang, {Ming Te} and Lin, {Yuh Feng} and Lu, {Kuo Cheng}",
year = "2016",
month = "11",
day = "1",
doi = "10.3390/nu8110708",
language = "English",
volume = "8",
journal = "Nutrients",
issn = "2072-6643",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Cholecalciferol additively reduces serum parathyroid hormone and increases vitamin D and cathelicidin levels in paricalcitol-treated secondary hyperparathyroid hemodialysis patients

AU - Zheng, Jing Quan

AU - Hou, Yi Chou

AU - Zheng, Cai Mei

AU - Lu, Chien Lin

AU - Liu, Wen Chih

AU - Wu, Chia Chao

AU - Huang, Ming Te

AU - Lin, Yuh Feng

AU - Lu, Kuo Cheng

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia. This study evaluates the possible beneficial effects of combined vitamin D treatment (paricalcitol and cholecalciferol). Methods: Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled. All patients administered 2 mcg/day of paricalcitol and were randomly allocated into control group (placebo) or study group (cholecalciferol) for 16 weeks. Serum 25(OH)D3, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up. Results: iPTH levels decreased in the study group appropriately and were more significantly decreased at 16 weeks. Study group had significantly increased 25(OH)D3 levels. In addition, the study group had significantly increased serum hCAP-18 levels compared with control group. Correlation analysis showed a significant correlation between the percentage increase in serum hCAP-18 and 25(OH)D3 levels. Conclusions: Cholecalciferol, in combination with paricalcitol, additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation. A dose of 5000 IU/week of cholecalciferol could maintain serum 25(OH)D3 levels above 30 ng/dL as early as 8 weeks after beginning supplementation. Doubling of serum cathelicidin levels were noted after 16 weeks of cholecalciferol supplementation in 40% of study patients.

AB - Background: Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia. This study evaluates the possible beneficial effects of combined vitamin D treatment (paricalcitol and cholecalciferol). Methods: Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled. All patients administered 2 mcg/day of paricalcitol and were randomly allocated into control group (placebo) or study group (cholecalciferol) for 16 weeks. Serum 25(OH)D3, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up. Results: iPTH levels decreased in the study group appropriately and were more significantly decreased at 16 weeks. Study group had significantly increased 25(OH)D3 levels. In addition, the study group had significantly increased serum hCAP-18 levels compared with control group. Correlation analysis showed a significant correlation between the percentage increase in serum hCAP-18 and 25(OH)D3 levels. Conclusions: Cholecalciferol, in combination with paricalcitol, additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation. A dose of 5000 IU/week of cholecalciferol could maintain serum 25(OH)D3 levels above 30 ng/dL as early as 8 weeks after beginning supplementation. Doubling of serum cathelicidin levels were noted after 16 weeks of cholecalciferol supplementation in 40% of study patients.

KW - Cholecalciferol

KW - Human cathelicidin (hCAP-18)

KW - Maintenance hemodialysis (HD)

KW - Paricalcitol

KW - Secondary hyperparathyroidism (SHPT)

KW - Study

UR - http://www.scopus.com/inward/record.url?scp=84995530884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995530884&partnerID=8YFLogxK

U2 - 10.3390/nu8110708

DO - 10.3390/nu8110708

M3 - Article

C2 - 27827962

AN - SCOPUS:84995530884

VL - 8

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 11

M1 - 708

ER -